Analystreport

Adaptimmune Therapeutics plc (NASDAQ: ADAP) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $5.00 price target on the stock.

Adaptimmune Therapeutics plc - American Depositary Shares  (ADAP) 
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am Check Earnings Report